Shares of Heron Therapeutics Inc (NASDAQ: HRTX) are higher after a long wait to get regulatory approval for its non-opioid pain drug.
What Happened: San Diego, California-based Heron, a commercial-stage biotechnology company focused on developing treatments for unmet patient. Read More. Don t Miss Any Updates! News Directly in Your Inbox Subscribe to:
Heron Therapeutics’ combo drug for post-surgical pain wins FDA nod on third try
Heron Therapeutics’ combo drug for post-surgical pain wins FDA nod on third try
Heron Therapeutics is positioning its drug, Zynrelef, as a way to help patients avoid addictive opioid painkillers following surgery. The extended-release formulation offers analgesic effects over 72 hours when postsurgical pain is most severe and more likely to require pain management medication.
Shares0
The FDA has approved a Heron Therapeutics combination drug developed to treat postsurgical pain and help patients avoid the need for opioid painkillers, a regulatory decision that comes after the agency twice turned down applications from the biotech.
Print
San Diego biotech Heron Therapeutics received approval from the Food and Drug Administration on Thursday for a drug that dulls post-surgical pain.
The treatment, known as Zynrelef, tamps down inflammation and pain signals in the area where a surgeon has made a cut. Clinical trials show the drug reduces the need for powerful and potentially addictive opioids.
It’s Heron’s third approved product though the company first had to go through years
of back-and-forth with the FDA. With those discussions now resolved, CEO Barry Quart says Zynrelef is poised to help millions of surgical patients each year.
“We think that this is really an opportunity to completely change how pain management is done,” Quart said. “It’s also an opportunity to dramatically reduce the amount of opiates that go home with (patients).”